Tag Archives: PATIENTS

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

LOS ANGELES (Reuters) – Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc (GILD.O) and Novartis AG (NOVN.S), new data shows, helping explain why sales of the two products have not met rosy expectations. FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside… Read More »

Lilly’s Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

Print this page INDIANAPOLIS, May 13, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and… Read More »

Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs

After the FDA last year slapped a warning label on SGLT2 diabetes drugs, detailing risks of an infection with a rare flesh-eating bacteria, a team of researchers has come out with a new set of numbers—and a warning for doctors prescribing the drugs. In a study published in the Annals of Internal Medicine, researchers found… Read More »